Jeffrey Jerome Ludwig - 12 Feb 2024 Form 4 Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)

Role: Chief Commercial Officer
Signature: /s/ Gordon Esplin as attorney-in-fact for Jeffrey Jerome Ludwig
Issuer symbol: PBYI
Transactions as of: 12 Feb 2024
Net transactions value: $0
Form type: 4
Filing time: 14 Feb 2024, 18:00:24 UTC
Previous filing: 05 Jan 2024
Next filing: 02 Jul 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PBYI	Common Stock	Award	$0	+27,067	+27%	$0.000000	127,037	12 Feb 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PBYI	Stock Option (Right to Buy)	Award	$0	+37,466		$0.000000	37,466	12 Feb 2024	Common Stock	37,466	$6.36	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2024, January 1, 2025, July 1, 2025 and January 1, 2026, subject to the Grantee's continued service with the Company through the applicable vesting date.
F2	Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares subject thereto on each of July 1, 2024, January 1, 2025, July 1, 2025 and January 1, 2026, subject to the Optionee's continued service with the Company through the applicable vesting date.